Abstract
The present industry update covers the period 16 October–15 November 2012, with information sourced from mainly company press releases, regulatory and patent agencies. This month saw Novo Nordsk’s long-acting insulin product (degludec) gain approval from the US FDA. There were mixed fortunes for companies in the clinical trial area with Antares, Lilly and Biogen all reporting positive late clinical stage trials but Clovis reporting disappointing results for its lipid-conjugated metastatic pancreatic cancer product, CO-101. On the merger and acquisitions front Immune and EpiCyte agreed to merge and Reddy’s indicated that it wishes to acquire the Dutch company OctoPlus. Alnylam announced that it had finally resolved all on-going litigation over its lipid nanoparticle technology for RNAi therapeutics by agreeing to pay US$30 million to Tekmira to secure rights to manufacture its own lipid nanoparticle-based products.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
